Clinical trials: Anginal Pain
Chest Pain, Cardiovascular Diseases
PCP Use of a Gene Expression Test (Corus CAD or ASGES) in Coronary Artery Disease Diagnosis
This is a prospective, multi-center study examining the clinical impact of the Corus CAD (Age/Sex/Gene Expression score - ASGES) assay in approximately 250 evaluable subjects with no history of obstructive coronary artery disease…
- Conditions
- Chest Pain, Cardiovascular Diseases, Angina Pectoris, Coronary Artery Disease
- Trial name
- IMPACT-PCP (NCT01594411)
- Testing
- Corus CAD
- Where
- 4 sites in United States
- Volunteers
- 251 people
- Sponsor
- CardioDx
Angina, Coronary Occlusion
XIENCE PRIME Japan Post-Marketing Surveillance (PMS)
The objectives of the PMS are to observe the frequency, type, and degree of device deficiency to assure the safety of the new medical device (XIENCE PRIME) as well as to collect information on evaluation of the efficacy and…
- Conditions
- Angina, Coronary Occlusion, Coronary Artery Disease, Coronary Artery Stenosis
- Trial name
- NCT01721096
- Testing
- XIENCE PRIME - Long Length (LL), XIENCE PRIME - Core Size
- Where
- Japan
- Volunteers
- 536 people
- Sponsor
- Abbott Medical Devices
Myocardial Infarction, Unstable Angina
Myocardial Ischemia and Transfusion Pilot
The purpose of this study is to evaluate two approaches to red blood cell transfusion in anemic patients with acute coronary syndrome.
- Conditions
- Myocardial Infarction, Unstable Angina, Coronary Artery Disease
- Trial name
- MINT Pilot (NCT01167582)
- Testing
- Red blood cell transfusion
- Where
- 7 sites in United States
- Volunteers
- 110 people
- Sponsor
- Rutgers, The State University of New Jersey
Coronary Artery Disease, Atherosclerosis, Coronary
Safety and Effectiveness of the Orsiro Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions
The objective of this study is to assess the safety and efficacy of the Orsiro Sirolimus Eluting Coronary Stent System in the treatment of subjects with up to three native de novo or restenotic (standard PTCA only) coronary…
- Conditions
- Coronary Artery Disease, Atherosclerosis, Coronary, Myocardial Ischemia, Ischemic Heart Disease
- Trial name
- BIOFLOW-V (NCT02389946)
- Testing
- Orsiro DES, Xience DES
- Where
- 92 sites in United States, Australia and 11 more
- Volunteers
- 1,334 people
- Sponsor
- Biotronik, Inc.
Coronary Artery Disease
A Study of the Onset and Offset of Antiplatelet Effects Comparing Ticagrelor, Clopidogrel, and Placebo With Aspirin
The purpose of this study is to see how Ticagrelor, a new oral reversible anti-platelet medication, affects platelets. Anti-platelet agents are medications that block the formation of blood clots by preventing the clumping of…
- Trial name
- NCT00528411
- Testing
- Ticagrelor Tablets, Clopidogrel (over encapsulated) capsule, Aspirin Tablets
- Where
- 9 sites in United States, United Kingdom
- Volunteers
- 123 people
- Sponsor
- AstraZeneca
Ischemic Heart Disease, Unstable Angina
Technology-Based Intervention to Promote Heart Health After Cardiac Rehab (Mobile4Heart)
The purpose of this study is to determine whether using a mobile app increases adherence to a heart healthy prescription after discharge from a cardiac rehab program.
- Conditions
- Ischemic Heart Disease, Unstable Angina, Systolic Heart Failure, Cardiovascular Diseases
- Trial name
- Mobile4Heart (NCT03446313)
- Testing
- Movn Mobile App
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- University of California, San Francisco
Myocardial Infarction, Heart Failure
The Improving ATTENDance to Cardiac Rehabilitation Trial
The benefits of cardiac rehabilitation are well known. However, despite center based cardiac rehabilitation (CBCR) representing guideline-based care for patients with cardiovascular disease, most patients do not complete the…
- Conditions
- Myocardial Infarction, Heart Failure, Heart Valve Diseases, Cardiac Event
- Trial name
- iATTEND (NCT03646760)
- Testing
- HYCR, CBCR
- Where
- United States
- Volunteers
- 282 people
- Sponsor
- Henry Ford Health System
Stable Angina, Heart Failure
Plasmonic Nanophotothermal Therapy of Atherosclerosis
The investigators hypothesize that the nanoburning is a very challenging technique to demolish and reverse the plaque especially in combination with stem cell technologies promising the functional restoration of the vessel wall.
- Conditions
- Stable Angina, Heart Failure, Atherosclerosis, Multivessel Coronary Artery Disease
- Trial name
- NANOM-FIM (NCT01270139)
- Testing
- Transplantation of nanoparticles, Transplantation of iron-bearing nanoparticles, Stenting
- Where
- 4 sites in Netherlands, Russia
- Volunteers
- 180 people
- Sponsor
- Ural State Medical University
Refractory Angina, Raised Lipoprotein(a)>50mg/dL or >500mg/L
Lipoprotein Apheresis in Refractory Angina Study
The goal of this study is to determine the impact of apheresis on clinical parameters and symptoms of patients with refractory angina and raised Lp(a).
- Trial name
- NCT01796912
- Testing
- Lipoprotein Apheresis
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- Imperial College London
Acute Coronary Syndromes
Study to Learn When Platelets Return to Normal After One Loading Dose of Anti-platelet Drugs in Patients With Symptoms of Acute Coronary Syndromes
To investigate how platelets recover to normal function in subjects who have symptoms of a heart attack or unstable angina and who get a loading dose of prasugrel or clopidogrel for planned coronary angiography.
- Trial name
- NCT01107899
- Testing
- clopidogrel, prasugrel
- Where
- Germany
- Volunteers
- 29 people
- Sponsor
- Eli Lilly and Company
Coronary Heart Disease
Clinical Evaluation of Magnetic Resonance Imaging in Coronary Heart Disease-2
CE-MARC 2 is a randomised controlled trial to determine diagnosis and patient management in patients presenting to outpatient clinics with suspected stable angina.
- Trial name
- CE-MARC2 (NCT01664858)
- Testing
- 3T CMR, SPECT, CT calcium score
- Where
- 6 sites in United Kingdom
- Volunteers
- 1,202 people
- Sponsor
- University of Leeds
Coronary Artery Disease, Angina Pectoris
Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (PCI)
This study will evaluate the efficacy of ranolazine as compared with placebo when used as part of standard medical therapy in chronic angina subjects with incomplete revascularization post-percutaneous coronary intervention (PCI…
- Trial name
- RIVER-PCI (NCT01442038)
- Testing
- Ranolazine
- Where
- 218 sites in United States, Austria and 13 more
- Volunteers
- 2,651 people
- Sponsor
- Gilead Sciences